Filgrastim

Filgrastim is a granulocyte colony-stimulating factor(G-CSF) analog used to stimulate the proliferation and differentiation of granulocytes. It is produced by recombinant DNA technologyand is marketed under the trade name "Neupogen." The gene for human granulocyte colony-stimulating factor is inserted into the genetic material of Escherichia coli. The G-CSF then produced by E. coli is only slightly different from G-CSF naturally made in humans.

Therapeutic uses

Filgrastim is used to treat neutropenia(a low number of neutrophils), stimulating the bone marrowto increase production of neutrophils. Causes of neutropenia include chemotherapyand bone marrow transplantation. Filgrastim is also used to increase the number of myeloid stem cellsbefore collection by leukapheresis.

Contraindications

Filgrastim should not be used in patients with known hypersensitivity to E. coli-derived proteins.

Adverse effects

The most commonly observed adverse effect is mild-to-moderate bone pain after repeated administration and local skin reactions at the site of injection.

External links

• [1]- Filgrastim information from Medline

References

• "Myeloid Growth Factors and Thrombopoietin." Drug Benefits and Risks: International Textbook of Clinical Pharmacology. (2001). ISBN 0-471-89927-5
• "Neupogen Prescribing Information." http://www.neupogen.com/pi.html. Accessed 10/20/05.

This article is licensed under the GNU Free Documentation License.
It uses material from the http://en.wikipedia.org/wiki/Filgrastim Wikipedia article Filgrastim.